stockrowProtalix BioTherapeutics, Inc.
PLXProtalix BioTherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $52.7 million, down 1.23% from fiscal 2024.
- Revenue
- +27.1%
- EPS
- +2,281.0%
- Free cash flow
- −94.1%
Quarter to June 2026, against a year earlier
Follow PLX
Alert me
Protalix BioTherapeutics, Inc. (PLX) EV/Sales
As of 6 November 2026, Protalix BioTherapeutics, Inc. (PLX) trades at a EV/Sales of 2.3×. Over the past ten years it has ranged from −105× (May 2015) to 65.3× (January 2015); the current reading is higher than 60% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.5× | 8.63% |
| FY2024 | 2.3× | 51.57% |
| FY2023 | 1.5× | (1.12%) |
| FY2022 | 1.5× | 128.28% |
| FY2021 | 0.7× | (41.61%) |
| FY2020 | 1.1× | (23.78%) |
| FY2019 | 1.5× | (8.38%) |
| FY2018 | 1.6× | (60.01%) |
| FY2017 | 4.1× | — |
| FY2016 | −0.2× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.0× | 10.47% |
| Mar 2026 | 1.9× | (25.09%) |
| Dec 2025 | 2.5× | (8.22%) |
| Sep 2025 | 2.7× | 61.95% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ELDN Eledon Pharmaceuticals, Inc. compare | n/m |
| DRUG Bright Minds Biosciences Inc. compare | n/m |
| ARTV Artiva Biotherapeutics, Inc. compare | n/m |
| PLX Protalix BioTherapeutics, Inc. | 2.3× |
| RNAC Cartesian Therapeutics, Inc. compare | 77.4× |
| SLGL Sol-Gel Technologies Ltd. compare | 121× |
| PALI Palisade Bio, Inc. compare | 151× |
| IKT Inhibikase Therapeutics, Inc. compare | 395× |
| IFRX InflaRx N.V. compare | 1,845× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)